Trial · NCT05725902
Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
NCT05725902, Phase 2, Completed, Novo Nordisk A/S
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease. Trials, record NCT05725902. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05725902
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease
- NCT number
- NCT05725902
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 12 participants, actual
- Lead sponsor
- Novo Nordisk A/S
- Conditions
- Sickle Cell Disease
- Interventions
- Etavopivat
- First posted
- 2023-02-13
- Last updated
- 2026-04-08
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Effect of etavopivat on cerebral blood flow (CBF) | 24 weeks | Change in cerebral blood flow (CBF) assessments from baseline will be summarized with descriptive statistics by nominal study visit. |
| Primary | Effect of etavopivat on oxygen ejection fraction (OEF) | 24 weeks | Change in OEF assessments from baseline will be summarized with descriptive statistics by nominal study visit. |
| Primary | Effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2) | 24 weeks | Change in CMRO2 assessments from baseline will be summarized with descriptive statistics by nominal study visit. |
| Secondary | Relationship between CBF and change in Hb levels | 24 weeks | The change from baseline of CBF will be correlated to the corresponding post-baseline assessment for change in Hb. |
| Secondary | Relationship between oxygen ejection fraction (OEF) and change in Hb levels | 24 weeks | The change from baseline of OEF will be correlated to the corresponding post-baseline assessment for change in Hb. |
| Secondary | Relationship between cerebral metabolic rate of oxygen (CMRO2) and change in Hb levels | 24 weeks | The change from baseline of CMRO2 will be correlated to the corresponding post-baseline assessment for change in Hb. |
| Secondary | Adverse events in participants with SCD | 24 weeks | Maximum intensity of treatment emergent adverse events (TEAEs) will be summarized by system organ class and preferred term. The tabulation of deaths, serious TEAEs, serious drug-related TEAEs and TEAEs leading to study drug discontinuation will also be provided |
| Secondary | Muscle hemodynamic effect of etavopivat on muscle blood flow | 24 weeks | Change in muscle blood flow assessments from baseline will be summarized with descriptive statistics by nominal study visit. |
| Secondary | Muscle hemodynamic effect of etavopivat on oxygen ejection fraction (OEF) | 24 weeks | Change in OEF from baseline will be summarized with descriptive statistics by nominal study visit. |
| Secondary | Muscle hemodynamic effect of etavopivat on cerebral metabolic rate of oxygen (CMRO2) | 24 weeks | Change in CMRO2 from baseline will be summarized with descriptive statistics by nominal study visit. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05725902
GET https://conductscience.org/api/trials/v1/NCT05725902/registered